Natera Inc
(NAS:NTRA)
$
162.39
0.4 (0.25%)
Market Cap: 21.44 Bil
Enterprise Value: 20.99 Bil
PE Ratio: 0
PB Ratio: 22.95
GF Score: 70/100 Natera Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022 / 05:00PM GMT
Release Date Price:
$32.45
(+2.40%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
I'm Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. We have the pleasure of hosting Natera this morning. Steve Chapman, Chief Executive Officer; and then Mike Brophy, Chief Financial Officer, will be on his way. But Steve, thanks for being here.
Steven Leonard Chapman
Natera, Inc. - CEO, President & Director
Yes. Thanks for having us. Appreciate it.
Questions & Answers
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Maybe if we start, you can kind of set the stage for us and go over some of the sort of key highlights this year and what investors should be focused over the balance of the year.
Steven Leonard Chapman
Natera, Inc. - CEO, President & Director
Yes. So Natera is the market leader in cell-free DNA testing, and we have deployed our technology in 3 very large areas of health care: in women
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot